UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000033873 |
|---|---|
| Receipt number | R000038632 |
| Scientific Title | Study for evaluating the safety of excessive intake of food containing plant-derived constituent |
| Date of disclosure of the study information | 2018/09/01 |
| Last modified on | 2019/02/22 11:21:06 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study for evaluating the safety of excessive intake of food containing plant-derived constituent
Acronym
Study for evaluating the safety of excessive intake of food
Scientific Title
Study for evaluating the safety of excessive intake of food containing plant-derived constituent
Scientific Title:Acronym
Study for evaluating the safety of excessive intake of food
Region
| Japan |
Condition
Condition
None (Healthy adults)
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the safety of excessive intake of food containing plant-derived constituent
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1. Interview by physician
2. Height and body weight
3. Blood pressure and pulse
4. Hematological test
5. Biochemical test
6. Urine analysis
7. Subjective symptom and objective response
8. Adverse events
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Food containing plant-derived constituent, 12 portion of food per day for 4 weeks.
Interventions/Control_2
Placebo food, 12 portion of food per day for 4 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1)Healthy males and females aged from 20 to less than 65 years old when giving the informed consent.
(2)Subjects with BMI from 18.5 to less than 30 kg/m2 at the screening.
(3)Subjects giving the informed consents in writing after receiving explanation of the purpose and details of the study, understanding the study and deciding to attend the study with their own will.
Key exclusion criteria
(1)Subjects on a diet.
(2)Subjects using medication affecting lipid metabolism.
(3)Subjects constantly using supplements or functional foods affecting lipid metabolism (including foods for specified health uses and foods with function claims).
(4)Subjects using foods containing ingredients of test food constantly.
(5)Subjects with excessive alcohol-drinking behaviors (maximum daily quantity: approximately 20 g of pure alcohol per day).
(6)Subjects who cannot stop drinking for two days until the screening and each checkup.
(7)Subjects with food allergy.
(8)Subjects with serious diseases (e.g., diabetes, kidney disease, liver disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorders.
(9)Subjects with chronic diseases and using medicines continuously.
(10)Subjects having a medical history of diseases affecting digestion and absorption.
(11)Subjects with implantable medical devices (e.g., cardiac pace maker and implantable defibrillator)
(12)Subjects judged unsuitable for the study based on the results of blood test.
(13)Subjects with anemia.
(14)Subjects having donated over 200 mL of blood or blood component within the last one month prior to the current study or over 400 mL of blood or blood component within the last three months prior to the current study.
(15)Subjects diagnosed with familial hyperlipidemia.
(16)Subjects under treatment or a history of drug addiction and/or alcoholism.
(17)Subjects participating or willing to participate in other clinical studies with the intake of food or pharmaceutical products, or with the swab of cosmetic or pharmaceutical products.
(18)Subjects who are pregnant, breastfeeding, or planning to be pregnant in the near future.
(19)Subjects working for a company developing or manufacturing functional foods.
(20)Subjects judged unsuitable for this study by the investigator for other reasons.
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshitaka Iwama |
Organization
Nihonbashi Cardiovascular Clinic
Division name
Director
Zip code
Address
Kyodo Building #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo, Japan
TEL
03-5641-4133
yiwama@well-sleep.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Eiji Yoshikawa |
Organization
KSO Corporation
Division name
Sales Department
Zip code
Address
Shibaura Omodaka Building 7F, 1-9-7 Shibaura, Minato-ku, Tokyo, Japan
TEL
03-3452-7733
Homepage URL
yoshikawa@kso.co.jp
Sponsor or person
Institute
KSO Co., Ltd
Institute
Department
Personal name
Funding Source
Organization
Kirin company, Limited
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 09 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 08 | Month | 09 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 09 | Month | 06 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 08 | Month | 23 | Day |
Last modified on
| 2019 | Year | 02 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038632
